372 articles with Medivir AB
Following the positive opinion given by the European Medicines Agency (EMA), the European Commission granted orphan medicinal product designation in the EU for MIV-818 for the treatment of patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer.
Medivir AB announced that Dr. Yilmaz Mahshid will assume his position as CEO on September 14, 2020. Uli Hacksell, who has been CEO since October 2018, will remain as a Board Member of Medivir.
Medivir AB announced that it has entered a research collaboration with the Drug Discovery and Development Platform at SciLifeLab on potential inhibitors of SARS CoV-2.
Medivir AB announced that the European Commission, in accordance with the opinion from the European Medicines Agency, has granted orphan medicinal product designation in the EU for MIV-818 for the treatment of patients with hepatocellular carcinoma, the most common type of primary liver cancer.
Medivir AB announced that its Board of Directors has appointed Yilmaz Mahshid as the new CEO of the company.
Medivir AB announced that the U.S. Food and Drug Administration has granted orphan drug designation to MIV-818 for the treatment of patients with hepatocellular carcinoma, the most common type of primary liver cancer.
Medivir's patent applications for MIV-818, covering both substance requirements for MIV-818 and its use for liver cancer treatment, were approved by the patent authorities in both the EU and Japan.
Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director The annual general meeting in Medivir Aktiebolag (publ) on 5 May 2020 resolved to approve the profit and loss accounts and balance sheets for the financial year 2019. The persons who had been board me
Medivir Receives Positive Opinion on Orphan Medicinal Drug Designation by the European Medicines Agency for MIV-818
Medivir AB announced that it has received positive opinion from the Committee for Orphan Medicinal Products on orphan medicinal product designation in the EU for MIV-818 for the treatment of patients with hepatocellular carcinoma, the most common type of primary liver cancer.
Medivir AB announces that Linda Basse, Chief Medical Officer at Medivir will leave the company on September 30, 2020.
Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2019 now is available at the company's website: www.medivir.com . The development in 2019 shows that the reorganization and refocus that was initiated at the end of 2018 was right for Medivir. Today we are an agile and efficient development company wit
The shareholders of Medivir AB are hereby summoned to the annual general meeting on Tuesday 5 May 2020 at 2 p.m. at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm..
Medivir AB announced that it has entered into a license agreement with US biotech company Tango Therapeutics for one of Medivir's preclinical research programs.
Medivir AB announced that the first patient with advanced liver cancer has been dosed in the phase Ib study of MIV-818.
Medivir Presents Positive Data From the Completed Phase Ia Study With MIV-818 in Patients With Advanced Liver Cancer
Medivir AB announces that new data from the completed phase Ia study with MIV-818 will be presented at the R&D day hosted by the company
Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to a R&D Day in Stockholm, Monday March 2, 2020, at 14:00 to 16:30 CET.
Medivir and Shijiazhuang Yuanmai Biotechnology Sign Licensing Agreement Regarding Manufacturing and Sales of Xerclear® in China
STOCKHOLM , Feb. 24, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announces today that the company has signed a licensing agreement for Medivir's Xerclear® for labial herpes with the Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd (SYB). The agreement gives SYB the right to register, manufacture and market the product in China . After market registrati
Continued progress with proprietary and wholly owned candidate drug MIV-818 for liver cancer
Medivir AB invites investors, analysts and the media to an R&D Day in Stockholm, Monday March 2, 2020, at 14:00 to 16:30 CET.
Medivir AB reports that the MIV-818 patent portfolio has been reinforced by the issue of notices of allowance from the European Patent Office and the Japanese Patent Office for the MIV-818 composition-of-matter and liver cancer treatment claims.